Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.

Deuruxolitinib is generally safe for treating alopecia areata.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This case report details a 57-year-old woman with frontal fibrosing alopecia who developed hyperpigmentation after treatment with dutasteride and pimecrolimus, highlighting no previously reported hyperpigmentation association with this combination.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This study found that prototype right heart circulatory assist devices significantly improved hemodynamics and reduced pulmonary vascular resistances in piglet models of acute hemodynamic shock.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

In rats with cyclophosphamide-induced hair loss, this study found that applying cetirizine HCl-loaded emulgel with microneedling stimulated hair growth, suggesting a potentially safer alternative to minoxidil for treating chemotherapy-induced alopecia.

Nano-liposol with astaxanthin may improve antioxidant and wound healing effects.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.